

Yamagata Med J (ISSN 0288-030X) 2018 ; 36(2) : 139-162

DOI 10.15022/00004447

Surgical management of sporadic pancreatic neuroendocrine tumor

Koji Tezuka, Wataru Kimura, Ichiro Hirai, Shuichiro Sugawara,
Toshihiro Watanabe, Yuya Ashitomi, Shintaro Nozu, Ryosuke Takahashi

Department of Gastroenterological, Breast, Thyroid and General Surgery, Yamagata University Faculty of Medicine
(Accepted May 30, 2018)

ABSTRACT

Recently, new treatment guidelines and classifications were proposed for the management of pancreatic neuroendocrine tumors (P-NETs), and are now being used in clinical practice. The World Health Organization classification published in 2010 emphasized the importance of a grading system for P-NETs based on parameters of proliferative activity, such as mitotic count and Ki-67 labeling index, proposed by the European Neuroendocrine Tumor Society. For surgical treatment of P-NETs, it is important to select a strategy based on the degree of tumor malignancy. However, there are still no clear indications for organ-preserving pancreatic resection or lymph node dissection. This article outlines the surgical management and clinicopathological features of P-NETs. There are various surgical options, such as tumor enucleation, spleen-preserving distal pancreatectomy (SpDP), distal pancreatectomy with splenectomy, pancreatoduodenectomy, and duodenum-preserving pancreatic head resection. Hepatectomy is the first choice for liver metastasis from well-differentiated neuroendocrine carcinoma without extrahepatic metastasis. Other treatment options are radiofrequency ablation, transarterial chemoembolization/ embolization, and liver transplantation. Systematic chemotherapy, biotherapy such as somatostatin analogue and interferon- α , and targeted therapy are used for recurrence after surgery and unresectable tumors. This article also gives details of the surgical techniques available for tumor enucleation and SpDP.

Key words: pancreatic neuroendocrine tumor, enucleation, spleen-preserving distal pancreatectomy, Liver metastasis

Introduction

Pancreatic neuroendocrine tumors (P-NETs) are comparatively rare neoplasms, and account for only 1%–2% of all pancreatic neoplasms. The incidence of P-NETs is approximately 1 per 100 000 people^{1)–5)}. The incidence in autopsy cases ranges from 0.26% to 1.4%^{6), 7)}. An autopsy study of 800 elderly subjects obtained specimens cut every 5 mm and found tiny neuroendocrine tumors (NETs) in more than 10% of the cases⁸⁾.

P-NETs include benign neoplasms without

metastasis or invasion, as well as high-grade malignant neoplasms. The assessment of tumor malignancy is important for determining the surgical strategy for P-NETs. In 2000 and 2004, the World Health Organization (WHO) classified P-NETs into three categories – well-differentiated NETs (benign or uncertain behavior), well-differentiated neuroendocrine carcinoma (NEC), and poorly differentiated NEC – according to the presence or absence of metastasis, direct invasion, arterial or venous invasion, perineural invasion, hormonal syndrome, tumor size, histological differentiation, and Ki-67 index^{9), 10)}.

Table 1. A grading system for neuroendocrine tumors proposed by the European Neuroendocrine Tumor Society [11, 12].

| Grade | Mitotic count (10 HPF) ^a | Ki-67 index (%) ^b |
|-------|-------------------------------------|------------------------------|
| G1 | <2 | ≤2 |
| G2 | 2-20 | 3-20 |
| G3 | >20 | >20 |

^a Ten HPF: High power field = 2 mm², at least 40 fields, evaluated in areas at highest mitotic density

^b MIB 1 antibody: Percent of 2,000 cells in areas of highest nuclear labeling

The European Neuroendocrine Tumor Society (ENETS) proposed guidelines for the treatment and prognostic stratification of gastroenteropancreatic NETs in 2006 by histological differentiation according to the WHO classification, the TNM classification, and grading based on proliferative activity, such as Ki-67 labeling index and mitotic count^{11),12)} (Table 1).

The American Joint Committee on Cancer (AJCC) proposed a new TNM classification for P-NETs in 2009¹³⁾. This classification is used for pancreatic ductal adenocarcinoma; the AJCC applied the same classification for P-NETs.

In the WHO classification published in 2010¹⁴⁾, the grading system proposed by the ENETS^{11),12)} was considered important. Well-differentiated NETs were classified into NET G1 and NET G2, and poorly differentiated carcinoma was classified into NEC¹⁴⁾ (Table 2). The 2000/2004 WHO histological classification included TNM elements such as tumor size and metastasis^{9),10)}, but in the 2010 WHO classification¹⁴⁾, the TNM classification (AJCC-TNM) was adopted for these factors. There are two major differences between the AJCC-TNM classification and the ENETS-TNM classification: the definition of the T stages and the consideration of tumor grading based on proliferative activity. Both TNM classifications are effective prognostic indicators¹⁵⁾⁻¹⁹⁾. However, they are not free of problems^{20),21)}. The fact that there are two TNM classifications actually causes confusion among many practitioners.

P-NET G3 was newly added to the well-differentiated pancreatic neuroendocrine neoplasm category of the WHO classification published in 2017²²⁾ (Table 3). Grade 3 (ki-67 > 20%) tumors include biologically distinct subtypes. For example, Sorbye et al. reported that Grade 3 tumors with Ki-

Table 2. The pathological classification of neuroendocrine tumors by World Health Organization classification [9, 10, 14]

| WHO (2000/ 2004) | WHO (2010) |
|---|---------------------------------|
| 1. Well-differentiated endocrine tumor (WDET) | Neuroendocrine tumor |
| 1.1. Benign behavior | NET G1 |
| Confined to the pancreas, nonangioinvasive, < 2cm in size, ≤2 mitoses and ≤2% Ki-67 positive cells/ 10HPF | NET G2 |
| 1.2. Uncertain behavior | |
| Confined to the pancreas, ≥2cm in size, >2 mitoses and >2% Ki-67 positive cells/ 10HPF, or angioinvasive | |
| 2. Well-differentiated endocrine carcinoma (WDEC) | |
| Low grade malignant with gross local invasion and/or metastases | |
| 3. Poorly-differentiated endocrine carcinoma (PDEC)/ small cell carcinoma, high grade malignant | Neuroendocrine carcinoma |
| | Large cell NEC |
| | Small cell NEC |

NET: Neuroendocrine tumour, NEC: Neuroendocrine carcinoma

67 < 55% had a lower response rate to platinum-based chemotherapy (15% vs. 42%, P < 0.001), but better survival than Grade 3 tumors with Ki-67 ≥ 55% (14 months vs. 10 months, P<0.001)²³⁾. Raj et al. reported that the response rate to platinum-based chemotherapy was 10% in Grade 3 well-differentiated P-NETs and 37% in poorly differentiated pancreatic NEC and that overall survival was significantly longer in Grade 3 well-differentiated P-NETs compared with G3 pancreatic NEC²⁴⁾. Well-differentiated P-NETs are more likely to have loss of nuclear expression of DAXX or ATRX, and preserved expression of Rb and p53^{25),26)}. Therefore, well-differentiated P-NET G3 is an entity that should be distinguished from poorly differentiated NEC.

In the 2017 WHO classification, the same TX-T3 factors used in the ENETS-TNM classification were applied for the T-factor in the TNM classification of well-differentiated pancreatic neuroendocrine neoplasms²²⁾ (Table 4). Distant metastases were subclassified as M1a for liver metastasis alone, M1b for extrahepatic metastasis alone, and M1c for concurrent liver metastasis and extrahepatic metastasis. Stage subclassifications were eliminated and replaced with a simple system divided into stages I, II, III, and IV. The TNM classification for pancreatic ductal adenocarcinoma was applied for pancreatic NEC²²⁾.

This article describes surgical strategies and options for the treatment of P-NETs.

Neuroendocrine tumor

Table 3. 2017 WHO classification and grading of pancreatic neuroendocrine neoplasms (PanNENs) [22].

| Classification/grade | Ki-67 proliferation index ^a | Mitotic index ^a |
|---|--|----------------------------|
| Well-differentiated PanNENs: pancreatic neuroendocrine tumours (PanNETs) | | |
| PanNET G1 | < 3% | < 2 |
| PanNET G2 | 3-20% | 2-20 |
| PanNET G3 | > 20% | > 20 |
| Poorly differentiated PanNENs: pancreatic neuroendocrine carcinomas (PanNECs) | | |
| PanNEC (G3) | > 20% | > 20 |
| Small cell type | | |
| Large cell type | | |
| Mixed neuroendocrine –non-neuroendocrine neoplasm | | |

^a The ki-67 proliferation index is based on the evaluation of ≥ 500 cells in areas of higher nuclear labelling (so-called hotspots). The mitotic index is based on the evaluation of mitoses in 50 high-power fields (HPF: 0.2mm² each) in areas of higher density and is expressed as mitoses per 10 high power fields (2.0 mm²). The final grade is determined based on whichever index (Ki-67 or mitotic) places the lumen in the highest grade category. For assessing Ki-67, casual visual estimation (eyeballing) is not recommended: manual counting using printed images is advocated.

Table 4. TNM classification of tumours of the neuroendocrine pancreas* [22].

| T-Primary Tumor | M-Distant Metastasis | | | |
|---|---|--------|-------|-------|
| TX Primary tumour cannot be assessed | M0 No distant metastasis | | | |
| T0 No evidence of primary tumour | M1 Distant metastasis | | | |
| T1 Tumour limited to pancreas**, less than 2cm in greatest dimension | M1a Hepatic metastasis only | | | |
| T2 Tumour limited to pancreas**, 2cm or more but less than 4cm in greatest dimension | M1b Extrahepatic metastasis only | | | |
| T3 Tumour limited to pancreas**, more than 4cm in greatest dimension or Tumour invading duodenum or bile duct | M1c Hepatic and extrahepatic metastases | | | |
| T4 Tumour perforates visceral peritoneum (serosa) or other organs or adjacent structures | | | | |
| N- Regional Lymph Nodes | Stage | | | |
| NX Regional lymph nodes cannot be assessed | Stage I | T1 | N0 | M0 |
| N0 No regional lymph node metastasis | Stage II | T2, T3 | N0 | M0 |
| N1 Regional lymph node metastasis | Stage III | T4 | N0 | M0 |
| | | Any T | N1 | M0 |
| | Stage IV | Any T | Any N | Any M |

*The TNM classification of PanNECs follows the criteria for classifying ductal adenocarcinomas.
** This includes invasion of the peripancreatic adipose tissue.

Surgical strategies for P-NETs

Surgical treatment for P-NETs varies according to the site and size of the tumor, whether single or multiple, benign or malignant, and associated with multiple endocrine neoplasia type 1 or not. Patients with nonfunctioning P-NETs < 1.0 mm, which are occasionally found at autopsy, are certainly not candidates for treatment. Approximately 70%–90% of enlarging P-NETs have malignant features, such as invasion and metastases^{(22)–(28)}. However, there are no definite indications regarding whether nonfunctioning P-NETs should be removed or observed based on size, since P-NETs are so rare that there is little evidence clarifying the size of tumors that should be treated^{(29)–(31)}. Functional P-NETs such as insulinoma and gastrinoma should be treated surgically, even if the tumor is < 1 cm. Despite the small size,

gastrinoma has malignant potential^{(32)–(35)}.

According to the ENETS guidelines, surgical resection is indicated for nonfunctioning P-NETs in patients who have symptoms, patients with a diagnosis of NET G2, and patients who desire to have surgery. They also recommend non-operative management as one of the therapeutic options for nonfunctioning P-NETs ≤ 2 cm if major pancreatic resection is required, and surgery is indicated if the tumor diameter increases by > 0.5 cm or to > 2 cm⁽³⁶⁾.

In contrast, according to the National Comprehensive Cancer Network guidelines, surgery is generally indicated for all patients, but observation may also be an option for patients with small P-NETs detected incidentally depending on factors such as comorbidities, surgical risk, and tumor location⁽³⁷⁾. The Japanese guidelines proposed by the

Japan Neuroendocrine Tumor Society recommend that all patients with nonfunctioning P-NETs are candidates for surgery regardless of tumor diameter as long as they are managed in the hospital where pancreatic surgery can be done safely and do not have contraindications to surgery such as severe comorbidities³⁸⁾.

Considering that some nonfunctioning P-NETs ≤ 2 cm are still highly malignant with metastatic potential^{39)–41)} and that analyses using the United States National Cancer Database have shown that surgical resection of nonfunctioning P-NETs ≤ 2 cm improves survival^{40), 42)}, surgery should be indicated for all nonfunctioning P-NETs. However, in studies that followed patients with nonfunctioning P-NETs ≤ 2 cm (median or mean size: 10 to 14 mm) that were asymptomatic (i.e., no epigastric pain, jaundice, pancreatitis, or symptoms associated with excessive hormone secretion) and had no invasion of peripancreatic tissue or lymph node or extrahepatic metastasis on imaging for a period of 31 to 45 months (median or mean), tumor growth of $\geq 20\%$ was reported in only 0% to 13% of patients and no metastases or disease-specific deaths were reported, even in patients who underwent surgery after observation^{43)–46)}. In a Japanese study that followed 19 patients with nonfunctioning P-NETs with a median size of 12 mm for a median period of 45 months, five-year progression-free survival was 83%⁴⁷⁾. The results of these studies suggest that observation with careful monitoring of progress may be feasible for a select group of patients with tumors ≤ 2 cm. Several studies have concluded that patients with nonfunctioning P-NETs < 15 mm, many of which are NET G1, are ideal candidates for observation^{46), 47)}. Moreover, Zhang et al. found that although surgical resection improves survival in patients with nonfunctioning P-NETs ≥ 15 mm, the significance of surgery is unclear in patients with nonfunctioning P-NETs < 15 mm⁴⁸⁾. Using size as an indicator, a cutoff of 15 mm may be one means of determining whether observation is also an option. In addition, studies have shown that survival outcomes are significantly worse for G2/3 nonfunctioning P-NETs ≤ 2 cm than for G1 tumors ≤ 2 cm and improved survival can be anticipated with surgical

resection in patients with G2/3 nonfunctioning P-NETs ≤ 2 cm^{49), 50)}. As such, surgery should always be performed for P-NET G2/3 patients regardless of tumor size.

Surgical treatment of primary tumors

In the WHO classifications published in 2000⁹⁾ and 2004¹⁰⁾, NETs were classified into benign behavior or uncertain behavior and well-differentiated NEC or poorly differentiated NEC. However, the WHO classification published in 2010 emphasized grade as recommended by ENETS^{11), 12)}, and NETs were classified into NET G1, NET G2, or NEC (G3) based on mitotic count and Ki-67 labeling index¹⁴⁾. The prognosis of Grade 2/3 P-NETs is significantly worse than that of Grade 1 P-NETs^{17), 18), 51)–55)}. Even if the tumor is small, radical surgery with regional lymph node dissection should be performed for Grade 2/3 P-NETs^{52), 56)}.

Determination of TNM classification and grade is important in deciding on a surgical strategy for the primary tumor because these are risk factors for postoperative recurrence.

Predictors of lymph node metastasis and grade (Tables 5, 6)

Tables 5 and 6 show predictors of lymph node metastasis^{41), 57)–80)} and grade^{46), 50), 67), 69), 71), 72), 78), 79), 81)–94)}.

The relationship between tumor diameter and lymph node metastasis has been well researched. Many studies have shown that the rate of lymph node metastasis is significantly higher for tumors > 15 to 20 mm^{41), 58)–69)}. Tumors > 15 to 20 mm are also more likely to be Grade 2/3^{46), 50), 67), 69), 84)–90)}, and thus tumor diameter is an important predictor of grade as well as lymph node metastasis. However, several studies have shown that tumor diameter is not an independent predictor of lymph node metastasis^{41), 60), 61), 69)}. Some studies have shown that even P-NETs < 10 mm are accompanied by lymph node metastasis in 10% to 30% of patients^{39), 40), 41), 65)}, and this may be partially attributable to the presence of patients with lymph node metastasis regardless of tumor diameter. Consequently, it is important to evaluate factors other than tumor diameter.

Nodal features suggestive of lymph node

Table 5. Reported predictive factors for lymph node metastasis of P-NETs

| Category I | Reference No. | |
|---|---|---|
| | Statistically significant difference | |
| | Presence | Absence |
| Lymph node | | |
| Enlargement (≥ 1 cm)/hypervascularization (CT) | 57[UM] | |
| A short axis measuring > 1 cm/abnormal round morphology/central necrosis (CT) | 58[UM] | |
| Tumor size | | |
| ≥ 15 mm | 41[U]/ 59[U], 60[U], 61[U] | 41[M], 60[M], 61[M] |
| > 17 mm/ > 18 mm | 62[U]/ 63[UM] | |
| ≥ 20 mm | 64[U], 65[UM], 66[UM] / 67[U] | 68[U], 69[M] |
| Tumor enhancement pattern | | |
| Hypoenhancement on arterial phase (CT) | 70[U] | |
| Hetero/hypo-attenuation in the late arterial phase (30 s) (CT) | 60[UM] | |
| Iso/hypo-attenuation in the pancreatic phase (44 s) | 71[U] | |
| Tumor to pancreas contrast ratio on portal venous phase (75 s) < 1.238 (CT) | 58[UM] | |
| Main pancreatic duct involvement (MRCP/CT) | 61[UM] | |
| Tumor shape irregular (CT) | 72[U] | |
| Laboratory findings | | |
| Neutrophil to lymphocyte ratio (NLR) ≥ 2.056 | 73[UM] | |
| Pathological factor | | |
| Grade G2/G3 | 41[U], 57[UM], 60[U], 61[U], 63[U], 74[UM], | 41[M], 60[M], 61[M] |
| Poorly/moderately differentiation | 68[UM] | |
| Lymph vascular invasion | 41[U], 68[U] | 41[M] |
| Positive CK19 expression | 75[U], 76[U] | |
| No hormonal expression for immunohistochemical study | 77[U] | |
| Gastrin/serotonin expression for immunohistochemical study | 77[U] | |
| Category II | | |
| Symptomatic (Non-functioning tumor) | 68[U], 74[UM], 78[U], 79[U] | 69[M], 57[U] |
| Tumor location Pancreatic head | 41[U], 57[U], 63[U], 66[UM], 69[M] | 41[M], 57[M], 58[U], 60[U], 61[U], 63[M], 65[U], 74[U], 80[U] |
| Vascular invasion (CT) | 58[U] | 58[M] |
| Tumor margin poorly defined (CT) | 58[U] | 58[M] |
| Intratumoral calcification (CT) | 80[UM] | 58[U], 60[U] |
| Tumor thrombus | 73[U] | 73[M] |
| Perineural invasion | 68[U] | 68[M] |

Definitions of Categories I and II:

Category I: Factors identified as potential predictors of lymph node metastasis by statistical or clinical analysis

Category II: Potential predictors of lymph node metastasis on which further research is warranted

U: univariate analysis; M: multivariate analysis

metastasis have also been investigated. Partelli et al. found that enlargement of the lymph nodes to ≥ 1 cm and/or hypervascularization of peripancreatic lymph nodes on contrast-enhanced CT were independent predictors of lymph node metastasis⁵⁷. Choi et al.

found that a nodal short axis diameter greater than 1cm, an abnormal round morphology, and central necrosis were independent predictors of lymph node metastasis⁵⁸.

Many studies have shown that tumor contrast

Table 6. Reported predictive factors for Grade 2/3 P-NETs

| Category | Reference No. | |
|---|---|--|
| | Statistically significant difference | |
| | Presence | Absence |
| Category I | | |
| Diagnosis of G2/3 by EUS-FNA | 81, 82, 83 | |
| Tumor growth ($\geq 20\%$ or 5 mm increase in size) | 46[U] | |
| Imaging findings | | |
| Tumor size | | |
| ≥ 15 mm/ > 17.5 mm | 46[UM]/84 | |
| $>/\geq 20$ mm | 50[U], 85[U], 69[M], 86[U], 87[U]/67[U], 88[U], 89[UM] | |
| ≥ 30 mm | 90[U] | |
| Tumor enhancement pattern | | |
| Non-homogenous hyper-attenuation on arterial phase (20-30 s) | 91[U] | |
| Iso/hypo-attenuation in the pancreatic phase (44 s) | 71[U] | |
| Tumor to pancreas contrast ratio on arterial phase (CT) < 1.1 (Predictive factor for grade 2/3) | 67[U] | |
| Late contrast enhancement (peak attenuation observed in the venous phase) (CT) | 67[U] | |
| Peripancreatic tissue invasion (MRI/CT) | 86[U], 90[U]/85[UM] | |
| Vascular invasion (MRI/CT) | 84[U], 86[U], 90[U] /87[U], 85[UM] | 88[U] |
| MPD involvement (MRI/EUS) | 90[U]/89[UM] | |
| ADC value (MRI) $\leq 1.22/1.21/0.930 \times 10^3$ mm ² /s | 84/ 92/ 93 | |
| ADC ratio [ADC value of the tumor (solid portion)/ ADC value of the parenchyma] < 0.94 | 91 | |
| Category II | | |
| Symptomatic (non-functioning tumor) | 78[U], 79[U] | 69[M] |
| Heterogenous enhancement (MRI/ CT) | 84[U], 94[U] / – | 92[U]/67[U], 86[U], 88[U] |
| MPD dilatation ≥ 4 mm (MRI/CT) | 86[U], 94[U]/87[U], 85[U] | 84[U], 90[U], 92[U]/85[M], 88[U], 91[U] |
| Ill-defined borders (MRI/CT) | 84[U], 94[U]/85[U] | 90[U], 94[U]/85[M], 88[U] |
| Tumor shape irregular/lobular (CT/EUS) | 72[U], 85[U], 91[U] / – | 85[M]/89[U] |
| Lymphadenopathy (≥ 10 mm) (with irregular margin and heterogenous enhancement) (CT) | 85[U], 87[U] | 85[M] |
| Internal echo pattern (EUS) heterogenous | 89[U] | 89[M] |

Definitions of Categories I and II:

Category I: Factors identified as potential predictors of Grade 2/3 P-NETs by statistical or clinical analysis

Category II: Potential predictors of Grade 2/3 P-NETs on which further research is warranted

U: univariate analysis; M: multivariate analysis

enhancement pattern is a predictor of lymph node metastasis and NET G2/3. A typical NET G1 exhibits homogeneous tumor staining reflecting hypervascularity in the early arterial phase or late arterial phase (pancreatic parenchymal phase) (20 to 44 s after injection of contrast medium)^{(60), (71), (95) – (99)}. In addition, they typically exhibit peak contrast enhancement in the early arterial (20 to 26 s) or late arterial (30 to 45 s) phase^{(71), (97), (100)}, followed by contrast medium washout in the portal venous phase (65 to 75 s) or equilibrium phase

(180 s)^{(71), (97), (99)}. In contrast, highly malignant tumors (NET G2/3) do not exhibit tumor staining in the arterial phase^{(60), (71), (99), (101)}, and exhibit peak contrast in the portal venous phase or equilibrium phase^{(67), (97), (102)}.

Invasion of the main pancreatic duct^{(61), (89), (90)}, invasion of peripancreatic tissue^{(85), (86), (90)}, and vascular invasion^{(84) – (87), (90)} have also been identified as predictors of lymph node metastasis or NET G2/3.

These studies indicate that it is necessary to consider not only tumor diameter but also features of peripancreatic lymph nodes, tumor contrast

enhancement patterns, and invasion of the main pancreatic duct, invasion of peripancreatic tissue, and vascular invasion when determining tumor malignancy.

Endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNA) is a method for grading tumors by direct collection of tumor tissue. However, one flaw of this method is that it underestimates the grade of NET G2/3 tumors with internal heterogeneity as the less malignant NET G1. Nevertheless, studies have shown that a preoperative pathological diagnosis of NET G2/3 by EUS-FNA often matches the postoperative pathological diagnosis^{81)–83)}.

Jung et al. found that tumors that grow by at least 20% or 5 mm in diameter are more likely to be NET G2/3, and that tumors that grow rapidly during observation must be treated as NET G2/3 as well⁴⁶⁾.

Many studies have shown that NET G1 exhibit high apparent diffusion coefficient (ADC) values on diffusion-weighted magnetic resonance imaging (MRI), and cutoff points ranging from 0.930 to 1.22 were found to have clinical utility^{84), 92), 93)}. In addition, Toshima et al. examined the ratio of ADC values of tumors and pancreatic parenchyma of the proximal side of the tumor to control for variation in ADC values by MRI scanner, and found that tumors with an ADC ratio (ADC value of the tumor/ADC value of the pancreatic parenchyma) of < 0.94 were often graded as NET G2/3, and ADC ratio was an independent predictor of grade⁹¹⁾.

Another study showed that SUVmax on FDG-PET is high in NET G3, and a cutoff value of 2.5 has clinical utility for differentiating between NET G3 and G1/2 patients¹⁰³⁾. Although differences between PET scanners may influence FDG-PET results as well, it can at least be assumed that tumors with low SUVmax are less malignant.

Some studies have shown that patients with nonfunctioning P-NETs who exhibit symptoms such as abdominal pain, jaundice, and weight loss are significantly more likely to have lymph node metastasis or NET G2/3^{68), 74), 78), 79)}. However, other studies have shown no significant difference^{57), 69)}. Findings common to all these studies are that symptomatic nonfunctioning P-NETs often

have a large tumor diameter and more advanced stage, with differences in these features manifesting as differences in grade of malignancy. However, Birnbaum et al. found that symptomatic patients, even those with tumors < 2 cm, were significantly more likely to have NET G2 or perineural invasion, and that lymph node metastasis also tended to be more common in symptomatic patients (25% vs. 9%, $P = 0.19$)⁷⁸⁾. In a study of 16 symptomatic patients with nonfunctioning P-NETs ≤ 2 cm, Sallinen et al. found that 7 patients with lymph node metastasis or liver metastasis had obstruction of the bile duct or main pancreatic duct⁵⁰⁾. Particular care is necessary in the evaluation of symptomatic patients with bile duct or main pancreatic duct invasion, even if the tumor size is ≤ 2 cm.

Although many studies have shown that lymph node metastasis is significantly more common in tumors of the pancreatic head^{41), 57), 63), 66), 69)}, many other studies have shown no significant difference^{6), 41), 57), 58), 60), 61), 63), 74), 80)}. As no study has shown that tumors of the pancreatic head are more likely to be NET G2/3, it is possible that lymph node metastasis of the tumors of the pancreatic head are more likely to occur than that of the tumors of the body or tail, if they are the same grade. At this point, it is necessary to evaluate lymph node metastasis risk comprehensively with consideration to other risk factors rather than relying on tumor location alone.

Although the extent of cystic component is not an independent predictor of NET G2/3^{85), 91)}, tumors with lymph node metastasis and NET G2/3 rarely have a large cystic component ($\geq 50\%$ of total tumor size)^{104), 105)}. Differential diagnosis from cystic tumors such as IPMN and MCN is also challenging for these types of NETs¹⁰⁴⁾.

Selection of surgical procedure (Tables 7, 8, 9)

There are currently no clear indications for organ-preserving resection, such as enucleation and spleen-preserving distal pancreatectomy (SpDP), in patients with P-NETs^{57), 106)–111)}.

Standard pancreatectomy with lymph node dissection is the treatment of choice when the tumor diameter is over 2 cm or lymph node metastasis or Grade 2/3 tumor is suspected preoperatively.

Table 7






Table 8



Essentially, pancreaticoduodenectomy is the treatment of choice for tumors of the pancreatic head, and distal pancreatectomy with splenectomy is the treatment of choice for tumors of the pancreatic body and tail (Tables 7, 8).

Standard pancreatectomy with lymph node dissection is also selected for functioning tumors other than insulinomas (Table 9)^{32)–35), 112)–115)}. Gastrinomas are particularly malignant, and even small gastrinomas have metastatic

Table 9



potential^{33), 35)}. Insulinomas ≤ 2 cm with no malignant features are almost always benign and are associated with favorable postoperative survival, so patients with such tumors are good candidates for organ-preserving surgery (Table 8)¹¹⁶⁾. Studies in which hormone production was evaluated by immunohistochemical study have shown that glucagon- and somatostatin-producing tumors are less likely to metastasize to the lymph nodes than gastrin- or serotonin-producing tumors⁷⁷⁾. However, glucagonomas and somatostatinomas that cause symptoms due to overproduction of hormones are often first detected in patients with advanced disease that has already metastasized to the liver^{112)–114)}.

Organ-preserving surgery is indicated for patients without risk factors such as lymph node metastasis (Table 5) or NET G2/G3 (Table 6). In specific terms, tumors that meet criteria such as size of < 15 mm, no peripancreatic lymph node features suggestive of lymph node metastasis, round or oval tumor morphology, well-defined tumor margins with no invasion of the main pancreatic duct or peripancreatic tissues, homogeneous tumor staining pattern on arterial-phase dynamic CT, low ADC relative to the pancreatic parenchyma on diffusion MRI, and lack of 20% or 5-mm growth during observation are relatively good candidates for organ-preserving surgery.

However, even patients with tumor diameter < 10 mm may have lymph node metastasis^{39)–41), 65)}, and conversely, some patients with a tumor diameter

of 15 to 20 mm may still be candidates for organ-preserving surgery as long as they do not have any other poor prognostic predictors such as lymph node metastasis or NET G2/3^{60), 61)}. Consequently, it is probably necessary to pay attention to factors other than tumor diameter as well.

One study on insulinomas found no difference in grade between tumors that did not show the typical tumor staining pattern in the arterial phase with those that did show the typical contrast pattern¹¹⁷⁾. This indicates that grading of insulinomas by contrast pattern alone should be avoided in favor of consideration alongside other findings when determining a surgical strategy.

Insulinomas < 20 mm that are located at the pancreatic margin far from the main pancreatic duct, are covered by a capsule, and have no other malignant features besides tumor diameter are good candidates for enucleation^{29), 116)}. SpDP or middle pancreatectomy are indicated for tumors of the pancreatic body or tail that are close to the main pancreatic duct, because injury of the main pancreatic duct may cause postoperative refractory pancreatic fistula and abdominal abscess. In that situation, duodenum-preserving pancreatic head resection (DPPHR) should be considered for tumors of the pancreatic head²⁹⁾. Nonfunctioning tumors of the pancreatic body or tail without risk factors such as lymph node metastasis or NET G2/3 that are far from the main pancreatic duct, are ≤ 1 cm, and are asymptomatic on detection are relatively good candidates for enucleation^{38), 65), 118)}.

SpDP with conservation of the splenic artery and vein (Kimura's method) does not include adequate dissection of the splenic hilar lymph nodes, but the same extent of dissection performed in standard surgery is technically feasible for dissection of lymph nodes surrounding the pancreatic body. SpDP may also be indicated for some nonfunctioning tumors of the pancreatic body that are > 15 mm in diameter but have no other malignant features.

Advantages of organ-preserving surgery include prevention of postoperative diabetes^{109), 119)}, preservation of pancreatic exocrine function^{109), 119), 120)}, and reduced risk of infection^{120), 121)}, new malignancies¹²³⁾, and

Table 10. Previously reported risk factors for recurrence after resection of the primary tumor without distant metastasis.

| Category | Reference No. | |
|---|---|---------------------------------------|
| | Statistically significant difference | |
| | Presence | Absence |
| Category I | | |
| Non-insulinoma | 128[UM] | |
| Imaging findings | | |
| Tumor size \geq 4 cm | 57[U], 68[U] | |
| Bile duct obstruction | 129[UM] | |
| Pancreatic duct obstruction | 129[UM] | |
| Pathological findings | | |
| Ki-67 index | | |
| \geq 2% | 128[UM] | |
| $>$ 20% | 41[UM] | |
| Grade (WHO): G2/3 | 50[UM], 57[UM], 94[U], 128[U], 130[U], 78[UM] | |
| Final resection status: R1 | 57[U], 131[UM] | 57[M] |
| Lymph node metastasis | 41[UM], 50[U], 57[UM], 74[UM], 128[UM], 130[U], 131[U] | 50[M], 68[U], 78[M], 131[M] 132[U] |
| Angioinvasion | 57[U], 74[UM], 132[U] | 57[M] |
| Tumor necrosis | 130[U] | |
| Well differentiated endocrine carcinoma (WHO 2004) | 130[U] | |
| Poorly/moderately differentiation | 68[U], 132[U] | |
| T stage: T3/4 (ENETS) | 128[UM] | |
| Category II | | |
| Symptomatic (non-functioning tumor) | 78[U], 133[M] | 50[U], 57[U], 74[U], 78[M] |
| Tumor size $>$ 2 cm | 74[U] | 68[U], 74[M] |
| Perineural invasion | 57[U], 74[U], 130[U], 131[U] | 57[M], 68[U], 74[M] |
| Lymphovascular invasion | 130[U] | 68[U], 131[U] |
| Elevation of CA19-9 | 74[U] | 74[M] |

Definitions of Categories I and II:

Category I: Factors identified as potential predictors of recurrence by statistical or clinical analysis

Category II: Potential predictors of recurrence on which further research is warranted

U: univariate analysis; M: multivariate analysis

thromboembolism^{122), 124)}. Consequently, it should be performed whenever possible when indicated.

As organ-preserving surgery does not include adequate lymph node dissection, sampling dissection of the peripancreatic lymph nodes should be performed intraoperatively when enlarged lymph nodes are detected around the tumor and standard surgery performed if metastasis is suspected.

Laparoscopic surgery has been widely performed for pancreatic neoplasms. The postoperative morbidity of laparoscopic surgery is comparable to that of open surgery^{125) - 127)}.

Although different institutions must establish their own eligibility criteria, laparoscopic surgery is

generally a good choice for less malignant tumors for which organ-preserving surgery would be indicated.

Risk factors for recurrence after primary tumor resection (Table 10)

Table 10 shows risk factors for recurrence after primary tumor resection^{41), 50), 57), 68), 74), 78), 94), 128) - 133)}. Recurrence of nonfunctioning tumors after enucleation or middle pancreatectomy has been reported in patients with characteristics such as NET G2 and lymph node metastasis^{110), 119)}. Recurrence of insulinomas has also been reported in patients with risk factors for recurrence such as NET G2, lymph node metastasis, and lymphovascular

invasion^{134),135)}. This indicates that depending on the surgical strategy (particularly enucleation or middle pancreatectomy), it may be necessary to consider and discuss the possibility of additional radical surgery with patients who have risk factors for recurrence such as lymph node metastasis, NET G2/3, moderately or poorly differentiated NETs, vascular invasion, or R1 resection as a result of histopathological evaluation after organ-preserving surgery. Potential cure through radical surgery is preferable to death resulting from local recurrence following organ-preserving surgery.

Surgical techniques for P-NETs

There are various surgical techniques for tumor enucleation and SpDP. Lymph node dissection should be performed for cases with lymph node metastases or obvious invasive findings. Pancreatoduodenectomy with combined portal vein resection or distal pancreatectomy with splenectomy is selected for advanced P-NET cases.

Enucleation for P-NETs

Enucleation is usually indicated for benign P-NETs. In particular, insulinomas, which are often diagnosed when < 2 cm, especially those measuring approximately 1 cm and projecting hemispherically from the surface of the pancreas and have a fibrous capsule surrounding the tumor^{29),136)}, tend to be resected using enucleation.

Enucleation can cause injury to the main pancreatic duct if the distance between the tumor and the main pancreatic duct is very small, and suturing of the pancreatic parenchyma after enucleation can cause stenosis of the main pancreatic duct. These injuries may result in postoperative refractory pancreatic fistula and abdominal abscess.

In such cases, SpDP with conservation of the splenic artery and vein (Kimura's method)^{136)–138)} and segmental pancreatectomy¹⁰⁹⁾ are also indicated for tumors of the body and tail of the pancreas. DPPHR may also be considered if the tumor is located deep in the head of the pancreas.

Preoperative computed tomography (CT), angiography, and EUS should be used to determine the presence of infiltration to neighboring organs and

capsule.

The number of multiple NETs in the pancreas and location of the tumors should be diagnosed preoperatively using CT, MRI, EUS, selective arterial calcium injection (SACI) test, and other modalities. Endoscopic ultrasonography is somewhat useful in detecting small P-NETs like insulinoma. The sensitivity of EUS for insulinoma is 83%–94%, and this increases to 96%–100% if EUS is combined with CT and MRI^{127),139)–141)}. A SACI test should be applied if the tumor cannot be detected with these modalities.

Advances in preoperative diagnostic modalities have allowed the detection of small P-NETs. Palpation and intraoperative ultrasonography should be performed to confirm the results of a preoperative diagnosis. An intraoperative diagnosis may be less accurate than a preoperative diagnosis, and requires a wider surgical field. This could lead to organ injury. Therefore, only tumors that are accurately diagnosed preoperatively should be resected²⁹⁾.

Preoperative stenting to the pancreatic duct through the papilla is useful for enucleation when the tumor is very close to the main pancreatic duct. Such stenting simplifies intraoperative detection of the main pancreatic duct. The surgeon can perform enucleation of the tumor safely without damaging the pancreatic duct¹⁴²⁾. Another technique uses injection of dye into the main pancreatic duct, which enables the surgeon to note leakage from the pancreatic branch duct. This technique requires the surgeon to be very familiar with the surgical anatomy of the pancreas¹⁴³⁾.

Spleen-preserving distal pancreatectomy with conservation of the splenic artery and veins (SpDP)

Preservation of the spleen in distal pancreatectomy has recently attracted considerable attention. Since the first trial and success with conservation of the splenic artery and vein for tumors of the pancreas and chronic pancreatitis, this procedure (Kimura's procedure)^{136),137)} has been performed very frequently. Splenic preservation can reduce the risk of hematological abnormalities, such as the elevation of serum platelet counts, thrombotic complications, and overwhelming postsplenectomy infection^{137),144)–146)}.

Enucleation is a common first-line therapy for benign P-NETs. However, enucleation can lead to injury of the main pancreatic duct if the distance between the tumor and the main pancreatic duct is very small, and so suturing of the pancreatic parenchyma after enucleation can cause stenosis of the main pancreatic duct. These injuries may result in postoperative refractory pancreatic fistula and abdominal abscess. SpDP with conservation of the splenic artery and vein (Kimura's procedure) may be desirable in such cases. Enucleation is also indicated if invasion to the pancreatic parenchyma is not clearly observed on imaging studies.

Surgical strategies for primary tumor with unresectable liver metastasis

Some reports have indicated a positive stance toward primary tumor resection for patients with P-NETs who have unresectable distant metastases because it is expected that this can improve the prognosis and quality of life of patients who have symptoms such as biliary and gastrointestinal obstruction, gastrointestinal bleeding, and abdominal pain^{27), 147) - 150)}. Furthermore, primary tumor resection makes it easier to select liver-targeted therapy, such as transarterial embolization (TAE) or transarterial chemoembolization (TACE). However, some authors have indicated that the effect of primary tumor resection in patients with unresectable liver metastasis is merely palliative, rather than improved outcome^{151), 152)}. Therefore, resection of the primary tumor in patients with unresectable liver metastasis from P-NETs is controversial.

Bloomston et al. have also reported that cytoreductive surgery at primary tumor resection (R2 resection) did not improve outcome, and in fact increased the incidence of postoperative complications¹⁵³⁾. It has also been reported that primary tumor resection should be avoided if liver metastasis shows a poorly differentiated histology, a Ki-67 labeling index of > 10%, and involves > 50% of the whole liver, because the outcome after primary tumor resection is very poor in such situations^{151), 154)}.

Resection of the primary tumor may be indicated for resectable symptomatic tumors or tumors that are considered likely to become symptomatic in the

near future, on the basis of prognostication from the extent of liver metastasis and the degree of tumor differentiation. In such cases, prophylactic cholecystectomy should be performed to prevent necrosis of the gallbladder following TAE/TACE. Palliative surgery such as a bypass operation may be indicated for bowel obstruction due to unresectable primary P-NETs.

Surgical treatment for liver metastasis

Hepatic resection combined with or without radiofrequency ablation is generally the first-line therapy for liver metastasis of P-NETs if there is no peritoneal dissemination or extra-abdominal metastasis, because they are usually slow-growing tumors^{155) - 157)}. Recently, the usefulness of ⁶⁸Ga-DOTATOC-PET/CT for detection of distant metastasis and staging has been reported^{158), 159)}. The 5- and 10-year survival rates for patients treated surgically for liver metastasis from NETs, including P-NETs, which account for 30-50% of all NETs in previous series, have been 61-86% and 35-50%^{155), 157), 160) - 167)}, respectively.

There has so far been no randomized control study comparing surgical with non-surgical treatment for resectable liver metastasis from NETs. However, liver resection has been performed for resectable liver metastasis as first line-therapy, because the prognosis of patients who undergo liver resection is better than that of patients who do not, with 5-year survival rates of 0-40%^{167) - 170)}. Recently, the Surveillance, Epidemiology, and End Results program of the National Cancer Institute United States, has demonstrated that the prognosis of patients with distant metastasis from P-NETs, for whom surgery was recommended but who declined, was significantly worse than that of patients who underwent surgery¹⁷¹⁾.

Partial resection, segmental resection, subsegmental resection, and lobectomy of the liver can also be considered based on the site and number of liver metastases. Combination chemotherapy with cisplatin and etoposide or irinotecan, instead of hepatectomy, is the first-line therapy for liver metastasis of NEC as defined by the 2010 WHO classification¹⁷²⁾.

Frilling et al. reported that prognosis and biological malignancy differed according to the localization and number of liver metastases^{158),173)}, and the ENETS guidelines suggest a therapeutic strategy that is based on this concept¹⁷²⁾.

The 5-year recurrence rate of liver metastasis after surgical treatment is very high, exceeding 80%. Most such recurrences occur within 2 years after surgery, and the most common sites are the liver, bone, lung, lymph nodes, peritoneum, and brain, the liver accounting for 80-90% of all recurrence sites^{161), 163) – 165), 167), 168), 174)}. Elias et al. reported that the preoperative detection rate for liver metastases by somatostatin receptor scintigraphy, CT, MRI, and abdominal ultrasonography was < 50% in comparison with final histological examination of liver specimens that had been systematically cut into 3- to 4-mm slices¹⁷⁵⁾. Control of such micrometastases is a major problem to be resolved in the future, in order to improve liver surgery outcomes¹⁷⁶⁾.

Simultaneous resection of primary P-NETs and liver metastasis carries a potential risk of fatal morbidity, such as bleeding due to pancreatic fistula and liver failure, and requires careful treatment decision-making. Sarmiento et al. reported that the rates of major morbidities such as bile leakage and pancreatic fistula, and mortality after distal pancreatectomy combined with liver resection were 18% and 0%, respectively¹⁶⁰⁾. Kianmanesh et al. reported two-step surgery for synchronous bilobar liver metastasis from digestive NETs including P-NETs of the distal pancreas. According to that report, at first-step surgery, distal pancreatectomy, partial resection of the left hepatic lobe, and ligation of the right portal vein were performed. For second-step surgery 8 weeks later, a right or extended right hepatectomy was performed. Using this strategy, morbidity and mortality rates were approximately 20% and 0%, respectively¹⁷⁷⁾. With adequate surgical planning and in specialized centers, surgical treatment of synchronous liver metastasis and P-NETs of the distal pancreas may be performed safely. In relation to combined surgery, pancreatoduodenectomy, and extended liver surgery, one study found that combined surgery was associated with a high mortality rate of 38% (3/8

cases)¹⁷⁸⁾. In this situation, careful decision-making about surgical indications is necessary.

Complete surgical resection is often difficult for liver metastasis, since 86% of patients with liver metastasis already have unresectable multiple liver metastases and extrahepatic metastases¹⁷⁹⁾. For unresectable liver metastases, liver transplantation, transarterial chemoembolization/embolization^{180), 181)} systemic chemotherapy¹⁸²⁾, biotherapy such as somatostatin analogue and interferon- α ¹⁸³⁾, peptide receptor radionuclide therapy (PRRT)¹⁸⁴⁾ and targeted therapy^{185), 186)} have been selected based on the presence or absence of extrahepatic metastasis, tumor proliferative activity, and somatostatin receptor status^{134), 155), 169)}. It has been reported that a small number of patients with an inoperable primary tumor and metastasis can achieve down-sizing and curative resection by the use of PRRT^{159), 184)}.

Liver transplantation for patients with liver metastases from P-NETs is indicated if the metastases are unresectable and no extrahepatic metastasis is present, although subsequent recurrence rates are very high¹⁷²⁾. Lehnert et al. reviewed 103 patients who underwent liver transplantation for liver metastasis from NETs and reported that their 5-year overall and recurrence-free survival rates were 47% and < 24%, respectively; the postoperative mortality rate within 60 days after liver transplantation was 14%¹⁸⁷⁾. Favorable prognostic factors after liver transplantation are a well-differentiated tumor histology, positive immunoreactivity for E-cadherin, a Ki-67 labeling index of < 5-10%, and liver metastasis involving < 40% of total liver volume^{188)–190)}. Le Treut et al. reported that liver transplantation for P-NETs is associated with poor prognosis, along with upper abdominal exenteration, liver transplantation for liver metastasis from duodenal NETs, and hepatomegaly¹⁹¹⁾. In a review of liver transplantation for liver metastasis from P-NETs, however, Máthé et al. concluded that liver transplantation for patients < 55 years of age who did not undergo resection of the primary tumor and liver transplantation simultaneously had a relatively good outcome, with a 5-year survival rate of 61%¹⁹²⁾. Thus, liver

transplantation may improve outcomes for selected patients.

Cytoreductive hepatic surgery, which removes 90% of liver metastases, may be indicated for hormonal symptoms that are resistant to medical therapy, to reduce the amount of hormone and improve clinical symptoms and prognosis, and may even increase long-term survival^{193)–195)}. The rate of remission of hormonal symptoms by cytoreductive hepatic surgery has been reported to be approximately 90%^{160), 161), 193), 196), 197)}. Furthermore, Chung et al. have reported that the rate of remission of hormonal symptoms by cytoreduction removing at least 70-90% of the tumor burden, followed by administration of an adjuvant long-acting somatostatin analog, was 87%¹⁹⁸⁾. Although Osborne et al. have indicated improvement of prognosis using cytoreductive hepatic surgery¹⁹⁷⁾, there is insufficient evidence for the efficacy of cytoreductive hepatic surgery for patients other than those who have hormonal symptoms resistant to medical therapy.

Surgical treatment for other sites of metastasis

There are few reports about surgical treatment for lung metastasis from NETs¹⁹⁹⁾. Although it is difficult to suggest any definitive therapeutic approach, patients who have no metastasis other than in the lung, metastatic tumors with low proliferative rates, and sufficient pulmonary function to tolerate lung resection may be suitable candidates for resection of lung metastasis.

In relation to peritoneal metastasis, 82-97% of patients with peritoneal metastasis from NETs have liver metastasis, and liver metastasis is a prognostic factor for patients with peritoneal metastasis^{200), 201)}. In addition, extrahepatic metastasis such as peritoneal metastasis is a poor prognostic factor for patients with liver metastasis^{165), 167)}. Therefore, therapy for liver metastasis and peritoneal metastasis may be important for improving prognosis. In terms of therapy for peritoneal metastasis, Ellias et al. reported that the 5- and 10-year survival rates for patients who had liver and peritoneal metastasis from well-differentiated NETs and who underwent resection of these metastases along with intraperitoneal chemotherapy using mitomycin C

and 5-fluorouracil were 71% and 31%, respectively; the outcome was unaffected by whether peritoneal metastasis was present or not¹⁵⁷⁾. Resection of peritoneal metastasis may be indicated if it can be done safely, as a part of combined therapy.

Local recurrence may also be an indication for surgery if the tumor is resectable. Schurr et al. reported that aggressive resection for recurrences including local recurrence had a tendency to improve overall and disease-free survival¹²⁰²⁾.

Postoperative surveillance for P-NETs

Postoperative follow-up for at least 10 years is needed because long-term recurrence can occur after surgery²⁰³⁾. Laboratory investigations and ultrasonography are required every 3 months during the first 2 years and CT is required every 6 months. Thereafter, laboratory investigations and ultrasonography are recommended every 6 months and CT is recommended yearly²⁰⁾.

Multiple primary cancers such as breast, prostate, bladder, and ovarian cancer occurred in 13% of P-NETs and approximately 20% of gastrinoma and nonfunctioning P-NETs³¹⁾. Therefore, careful observation and follow-up are required due to the possibility of multiple primary cancers.

Blood levels of gastrin, insulin, glucagon, and others can be used as indicators of recurrence of functioning P-NETs. Neuron-specific enolase is used as a tumor marker for poorly differentiated NETs²⁰⁴⁾. Somatostatin receptor scintigraphy^{205), 206)} and serum chromogranin A are used in postoperative follow-up²⁰⁷⁾. Serum chromogranin A is useful for determining recurrence and the effect of treatment, regardless of whether P-NET is functioning or nonfunctioning^{208)–210)}. Single-photon emission CT imaging in somatostatin receptor scintigraphy gave a sensitivity of 92.3% for liver metastases. This value is superior to those for planar imaging (58.5%) and CT, MRI, and ultrasonography (80%)²¹¹⁾.

Conflicts of interest

The authors have no conflicts of interest to declare.

Abbreviations

AJCC, American Joint Committee on Cancer; CT, computed tomography; DPPHR, duodenum-preserving pancreatic head resection; ENETS, European Neuroendocrine Tumor Society; EUS, endoscopic ultrasonography; FDG-PET, fluorodeoxyglucose positron emission tomography; FNA, Fine-needle aspiration; MRI, magnetic resonance imaging; NEC, neuroendocrine carcinoma; P-NET, pancreatic neuroendocrine tumor; PRRT, peptide receptor radionuclide therapy; SACI, selective arterial calcium injection test; SpDP, spleen-preserving distal pancreatectomy; TACE, transarterial chemoembolization; TAE, transarterial embolization; WHO, World Health Organization.

References

1. Eriksson B, Oberg K: Neuroendocrine tumours of the pancreas. *British Journal of Surgery* 2000; 87: 129-131
2. Lam KY, Lo CY: Pancreatic endocrine tumour: a 22-year clinico-pathological experience with morphological, immunohistochemical observation and a review of the literature. *Eur J Surg Oncol* 1997; 23: 36-42
3. Moldow RE, Connelly RR: Epidemiology of pancreatic cancer in Connecticut. *Gastroenterology* 1968; 55: 677-686
4. Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, et al. : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. *J Gastroenterol* 2010; 45: 234-243
5. Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. *Endocr Relat Cancer* 2008; 15: 409-427
6. Frantz VK: Islet Cell Tumors. In: Frantz VK, ed. *Tumor of the Pancreas*. Washington DC; AFIP, 1959: 79-141
7. Friesen SR, Tomita T: The APUD concept of islet cell tumors. In: Howard JM, ed. *Surgical Disease of the Pancreas*. Philadelphia; Lea & Febiger, 1987: 803-813
8. Kimura W, Kuroda A, Morioka Y: Clinical pathology of endocrine tumors of the pancreas. *Analysis of autopsy cases. Dig Dis Sci* 1991; 36: 933-942
9. Solcia E, Kloppel G, Sobin LH, in collaboration with 9 pathologists from 4 countries: Histological typing of endocrine tumours, World Health Organization International Histological Classification of Tumours, 2nd ed. Berlin; Springer, 2000
10. Heitz PU, Komminoth P, Perren A, Klimstra DS, Dayal Y, Bordi C, et al. : Pancreatic endocrine tumours: introduction. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. *World Health Organization Classification of Tumours, Pathology and Genetics, Tumours of Endocrine Organs*. Lyon; IARC Press, 2004: 177-182
11. Klöppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, et al. : ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. *Neuroendocrinology* 2009; 90: 162-166
12. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. : TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. *Virchows Arch* 2006; 449: 395-401
13. Sobin LH, Gospodarowicz MK, Wittekind C, eds. *International Union Against Cancer (UICC): TNM Classification of Malignant Tumors*, 7th ed. Oxford; Wiley-Blackwell, 2009
14. Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. *WHO Classification of Tumours of the Digestive System*, 4th ed. Lyon; IARC press, 2010
15. Bilimoria KY, Bentrem DJ, Merkow RP, Tomlinson JS, Stewart AK, Ko CY, et al. : Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. *J Am Coll Surg* 2007; 205: 558-563
16. La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A, et al. : Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. *Hum Pathol* 2009; 40: 30-40
17. Pape UF, Jann H, Müller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, et al. : Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. *Cancer* 2008; 113: 256-265
18. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B: Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. *Clin Cancer Res* 2008; 14: 7798-7803
19. Fischer L, Kleeff J, Esposito I, Hinz U, Zimmermann

- A, Friess H, et al. : Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. *Br J Surg* 2008; 95: 627-635
20. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, et al. : Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. *Mod Pathol* 2010; 23: 824-833
21. Ferrone CR, Tang LH, Tomlinson J, Gonen M, Hochwald SN, Brennan MF, et al. : Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?. *J Clin Oncol* 2007; 25: 5609-5615
22. Lloyd RV, Osamura RY, Klöppel G, Rosai J, eds. WHO classification of Tumours of Endocrine Organs, 4th ed. Lyon; IARC Press, 2017
23. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. : Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. *Ann Oncol* 2013; 24: 152-160
24. Raj N, Valentino E, Capanu M, Tang LH, Basturk O, Untch BR, et al. : Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated. *Pancreas* 2017; 46: 296-301
25. Tang LH, Untch BR, Reidy DL, O'Reilly E, Dhall D, Jih L, et al. : Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. *Clin Cancer Res* 2016; 22: 1011-1017
26. Singhi AD, Klimstra DS: Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases. *Histopathology* 2018; 72: 168-177
27. Franko J, Feng W, Yip L, Genovese E, Moser AJ: Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. *J Gastrointest Surg* 2010;14: 541-518
28. Bilimoria KY, Tomlinson JS, Merkow RP, Stewart AK, Ko CY, Talamonti MS, et al. : Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. *J Gastrointest Surg* 2007; 11: 1460-1469
29. Kimura W: Therapeutic surgical strategies for neuroendocrine tumors of pancreas (in Japanese),” *Suizo (Jpn J Panc Soc)* 2008; 23: 703-709
30. Triponez F, Dosseh D, Goudet P, Cougard P, Bauters C, Murat A, et al. : Epidemiology data on 108 MEN1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. *Ann Surg* 2006; 243: 265-272
31. Fendrich V, Waldmann J, Bartsch DK, Langer P: Surgical management of pancreatic endocrine tumors. *Nat Rev Clin Oncol* 2009; 6: 419-428
32. Oberg K, Eriksson B: Endocrine tumours of the pancreas. *Best Pract Res Clin Gastroenterol* 2005; 19: 753-781
33. Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M: Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. *Ann Surg* 2005; 242: 757-766
34. Lowney JK, Frisella MM, Lairmore TC, Doherty GM: Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size. *Surgery* 1998; 124: 1043-1049
35. Gurevich L, Kazantseva I, Isakov VA, Korsakova N, Egorov A, Kubishkin V, et al. : The analysis of immunophenotype of gastrin-producing tumors of the pancreas and gastrointestinal tract. *Cancer* 2003; 98: 1967-1976
36. Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. : ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. *Neuroendocrinology* 2016; 103: 153-171
37. Neuroendocrine tumors. Version 2.2017. NCCN clinical practice guidelines in oncology. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed 14 May 2017
38. Japan Neuroendocrine Tumor Society. Clinical Guideline for Pancreatic and Gastrointestinal Neuroendocrine Tumors, 1st ed. Tokyo; Kanehara, 2015 (in Japanese)
39. Haynes AB, Deshpande V, Ingkakul T, Vagefi PA, Szymonifka J, Thayer SP et al. : Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. *Arch Surg* 2011; 146: 534-538
40. Gratian L, Pura J, Dinan M, Roman S, Reed S, Sosa JA: Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States. *Ann Surg Oncol* 2014; 21:

- 3515-3521
41. Hashim YM, Trinkaus KM, Linehan DC, Strasberg SS, Fields RC, Cao D, et al. : Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). *Ann Surg* 2014; 259: 197-203
 42. Sharpe SM, In H, Winchester DJ, Talamonti MS, Baker MS: Surgical resection provides an overall survival benefit for patients with small pancreatic neuroendocrine tumors. *J Gastrointest Surg* 2015; 19: 117-123
 43. Lee LC, Grant CS, Salomao DR, Fletcher JG, Takahashi N, Fidler JL, et al. : Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. *Surgery* 2012; 152: 965-974
 44. Gaujoux S, Partelli S, Maire F, D'Onofrio M, Larroque B, Tamburrino D et al. : Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors. *J Clin Endocrinol Metab* 2013; 98: 4784-4789
 45. Crippa S, Partelli S, Zamboni G, Scarpa A, Tamburrino D, Bassi C, et al. : Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors. *Surgery* 2014; 155: 145-153
 46. Jung JG, Lee KT, Woo YS, Lee JK, Lee KH, Jang KT, et al. : Behavior of Small, Asymptomatic, Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PNETs). *Medicine (Baltimore)* 2015; 94: e983
 47. Kishi Y, Shimada K, Nara S, Esaki M, Hiraoka N, Kosuge T: Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size. *Ann Surg Oncol* 2014; 21: 2882-2888
 48. Zhang IY, Zhao J, Fernandez-Del Castillo C, Braun Y, Razmdjou S, Warshaw AL, et al. : Operative Versus Nonoperative Management of Nonfunctioning Pancreatic Neuroendocrine Tumors. *J Gastrointest Surg* 2016; 20: 277-283
 49. Mirkin KA, Hollenbeak CS, Wong J: Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors \leq 2 cm. *J Surg Res* 2017; 211: 206-214
 50. Sallinen V, Haglund C, Seppänen H. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter? *Surgery* 2015; 158: 1556-1563
 51. La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C, et al. : Prognostic criteria in nonfunctioning pancreatic endocrine tumours. *Virchows Arch* 1996; 429: 323-333
 52. Pelosi G, Bresaola E, Bogina G, Pasini F, Rodella S, Castelli P, et al. : Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. *Hum Pathol* 1996; 27: 1124-1134
 53. Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, et al. : Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. *J Clin Oncol* 2002; 20: 2633-2642
 54. Sellner F, Thalhammer S, Stättner S, Karner J, Klimpfinger M: TNM stage and grade in predicting the prognosis of operated, non-functioning neuroendocrine carcinoma of the pancreas-a single-institution experience. *J Surg Oncol* 2011; 104: 17-21
 55. Yang Z, Tang LH, Klimstra DS: Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: Implications for prognostic stratification. *Am J Surg Pathol* 2011; 35: 853-860
 56. Zerbi A, Falconi M, Rindi G, Delle Fave G, Tomassetti P, Pasquali C, et al. : AISP-Network Study Group: Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases. *Am J Gastroenterol* 2010; 105: 1421-1429
 57. Partelli S, Gaujoux S, Boninsegna L, Cherif R, Crippa S, Couvelard A, et al. : Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs). *JAMA Surg* 2013; 148: 932-939
 58. Choi SH, Kim HJ, Kim SY, Byun JH, Kim KW, Song KB, et al. : Computed Tomography Features Predictive of Lymph Node Involvement in Patients With a Nonfunctioning Pancreatic Neuroendocrine Tumor. *Pancreas* 2017; 46: 1056-1063
 59. Tsutsumi K, Ohtsuka T, Mori Y, Fujino M, Yasui T, Aishima S, et al. : Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. *J Gastroenterol* 2012; 47: 678-685
 60. Mizumoto T, Toyama H, Terai S, Mukubou H, Yamashita H, Shirakawa S, et al. : Prediction of lymph node metastasis in pancreatic neuroendocrine tumors

- by contrast enhancement characteristics. *Pancreatology* 2017; 17: 956-961
61. Nanno Y, Matsumoto I, Zen Y, Otani K, Uemura J, Toyama H, et al. : Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor. *Ann Surg Oncol* 2017; 24: 1127-1133
 62. Regenet N, Carrere N, Boulanger G, de Calan L, Humeau M, Arnault V, et al. : Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: A French multicenter study. *Surgery* 2016; 159: 901-907
 63. Taki K, Hashimoto D, Nakagawa S, Ozaki N, Tomiyasu S, Ohmuraya M, et al. : Significance of lymph node metastasis in pancreatic neuroendocrine tumor. *Surg Today* 2017; 47: 1104-1110
 64. Toste PA, Kadera BE, Tatishchev SF, Dawson DW, Clerkin BM, Muthusamy R, et al. : Nonfunctional pancreatic neuroendocrine tumors <2 cm on preoperative imaging are associated with a low incidence of nodal metastasis and an excellent overall survival. *J Gastrointest Surg* 2013; 17: 2105-2013
 65. Curran T, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N: Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection. *J Gastrointest Surg* 2015; 19: 152-160
 66. Postlewait LM, Ethun CG, Baptiste GG, Le N, McInnis MR, Cardona K, et al. : Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy. *J Surg Oncol* 2016; 114: 440-445
 67. Belousova E, Karmazanovsky G, Kriger A, Kalinin D, Mannelli L, Glotov A, et al. : Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades. *Clin Radiol* 2017; 72: 150-158
 68. Wong J, Fulp WJ, Strosberg JR, Kvols LK, Centeno BA, Hodul PJ: Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience. *Am J Surg* 2014; 208: 775-780
 69. Ricci C, Taffurelli G, Campana D, Ambrosini V, Pacilio CA, Pagano N, et al. : Is surgery the best treatment for sporadic small (≤ 2 cm) non-functioning pancreatic neuroendocrine tumours? A single centre experience. *Pancreatology* 2017; 17: 471-477
 70. Worhunsky DJ, Krampitz GW, Poullos PD, Visser BC, Kunz PL, Fisher GA, et al. : Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. *HPB (Oxford)* 2014; 16: 304-311
 71. Hyodo R, Suzuki K, Ogawa H, Komada T, Naganawa S: Pancreatic neuroendocrine tumors containing areas of iso- or hypoattenuation in dynamic contrast-enhanced computed tomography: Spectrum of imaging findings and pathological grading. *Eur J Radiol* 2015; 84: 2103-2109
 72. Okabe H, Hashimoto D, Chikamoto A, Yoshida M, Taki K, Arima K, et al. : Shape and Enhancement Characteristics of Pancreatic Neuroendocrine Tumor on Preoperative Contrast-enhanced Computed Tomography May be Prognostic Indicators. *Ann Surg Oncol* 2017; 24: 1399-1405
 73. Tong Z, Liu L, Zheng Y, Jiang W, Zhao P, Fang W, et al. : Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study. *World J Surg Oncol* 2017; 15: 108
 74. Jiang Y, Jin JB, Zhan Q, Deng XX, Shen BY: Impact and Clinical Predictors of Lymph Node Metastases in Nonfunctional Pancreatic Neuroendocrine Tumors. *Chin Med J (Engl)* 2015; 128: 3335-3344
 75. Han X, Zhao J, Ji Y, Xu X, Lou W: Expression of CK19 and KIT in resectable pancreatic neuroendocrine tumors. *Tumour Biol* 2013; 34: 2881-2889
 76. Ali A, Serra S, Asa SL, Chetty R: The predictive value of CK19 and CD99 in pancreatic endocrine tumors. *Am J Surg Pathol* 2006; 30: 1588-1594
 77. Kim JY, Kim MS, Kim KS, Song KB, Lee SH, Hwang DW, et al. : Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors. *Am J Surg Pathol* 2015; 39: 592-601
 78. Birnbaum DJ, Gaujoux S, Cherif R, Dokmak S, Fuks D, Couvelard A, et al. : Sporadic nonfunctioning pancreatic neuroendocrine tumors: prognostic significance of incidental diagnosis. *Surgery* 2014; 155: 13-21
 79. Ge W, Zhou D, Xu S, Wang W, Zheng S: Surveillance and comparison of surgical prognosis for asymptomatic and symptomatic non-functioning pancreatic neuroendocrine tumors. *Int J Surg* 2017; 39: 127-134
 80. Poultsides GA, Huang LC, Chen Y, Visser BC, Pai RK, Jeffrey RB, et al. : Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis. *Ann Surg Oncol* 2012; 19: 2295-2303

81. Weynand B, Borbath I, Bernard V, Sempoux C, Gigot JF, Hubert C, et al. : Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: high reproducibility and inter-observer agreement of the Ki-67 labelling index. *Cytopathology* 2014; 25: 389-395
82. Farrell JM, Pang JC, Kim GE, Tabatabai ZL: Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria. *Cancer Cytopathol* 2014; 122: 770-778
83. Hasegawa T, Yamao K, Hijioka S, Bhatia V, Mizuno N, Hara K, et al. : Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors. *Endoscopy* 2014; 46: 32-38
84. De Robertis R, Cingarlini S, Tinazzi Martini P, Ortolani S, Butturini G, et al. : Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage. *World J Gastroenterol* 2017; 23: 275-285
85. Luo Y, Dong Z, Chen J, Chan T, Lin Y, Chen M, et al. : Pancreatic neuroendocrine tumours: correlation between MSCT features and pathological classification. *Eur Radiol* 2014; 24: 2945-2952
86. Canellas R, Lo G, Bhowmik S, Ferrone C, Sahani D: Pancreatic neuroendocrine tumor: Correlations between MRI features, tumor biology, and clinical outcome after surgery. *J Magn Reson Imaging* 2018; 47: 425-432
87. Canellas R, Burk KS, Parakh A, Sahani DV: Prediction of Pancreatic Neuroendocrine Tumor Grade Based on CT Features and Texture Analysis. *AJR Am J Roentgenol* 2018; 210: 341-346
88. Takumi K, Fukukura Y, Higashi M, Ideue J, Umanodan T, Hakamada H, et al. : Pancreatic neuroendocrine tumors: Correlation between the contrast-enhanced computed tomography features and the pathological tumor grade. *Eur J Radiol* 2015; 84: 1436-1443
89. Fujimori N, Osoegawa T, Lee L, Tachibana Y, Aso A, Kubo H, et al. : Efficacy of endoscopic ultrasonography and endoscopic ultrasonography-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors. *Scand J Gastroenterol* 2016; 51: 245-252
90. Manfredi R, Bonatti M, Mantovani W, Graziani R, Segala D, Capelli P, et al. : Non-hyperfunctioning neuroendocrine tumours of the pancreas: MR imaging appearance and correlation with their biological behaviour. *Eur Radiol* 2013; 23: 3029-3039
91. Toshima F, Inoue D, Komori T, Yoshida K, Yoneda N, Minami T, et al. : Is the combination of MR and CT findings useful in determining the tumor grade of pancreatic neuroendocrine tumors? *Jpn J Radiol* 2017; 35: 242-253
92. Kim JH, Eun HW, Kim YJ, Han JK, Choi BI: Staging accuracy of MR for pancreatic neuroendocrine tumor and imaging findings according to the tumor grade. *Abdom Imaging* 2013; 38: 1106-1114
93. Guo C, Zhuge X, Chen X, Wang Z, Xiao W, Wang Q: Value of diffusion-weighted magnetic resonance imaging in predicting World Health Organization grade in G1/G2 pancreatic neuroendocrine tumors. *Oncol Lett* 2017; 13: 4141-4146
94. Kim M, Kang TW, Kim YK, Kim SH, Kwon W, Ha SY, et al. : Pancreatic neuroendocrine tumour: Correlation of apparent diffusion coefficient or WHO classification with recurrence-free survival. *Eur J Radiol* 2016; 85: 680-687
95. Rockall AG, Reznick RH: Imaging of neuroendocrine tumours (CT/MR/US). *Best Pract Res Clin Endocrinol Metab* 2007; 21: 43-68
96. Ichikawa T, Peterson MS, Federle MP, Baron RL, Haradome H, Kawamori Y, et al. : Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. *Radiology* 2000; 216: 163-171
97. Cappelli C, Boggi U, Mazzeo S, Cervelli R, Campani D, Funel N, et al. : Contrast enhancement pattern on multidetector CT predicts malignancy in pancreatic endocrine tumours. *Eur Radiol* 2015; 25: 751-759
98. Kartalis N, Mucelli RM, Sundin A: Recent developments in imaging of pancreatic neuroendocrine tumors. *Ann Gastroenterol* 2015; 28: 193-202
99. Yano M, Misra S, Carpenter DH, Salter A, Hildebolt CF: Pancreatic Neuroendocrine Tumors: Computed Tomography Enhancement, But Not Histological Grade, Correlates With Tumor Aggression. *Pancreas* 2017; 46: 1366-1372
100. Fidler JL, Fletcher JG, Reading CC, Andrews JC, Thompson GB, Grant CS, et al. : Preoperative detection of pancreatic insulinomas on multiphasic helical CT. *AJR Am J Roentgenol* 2003; 181: 775-780
101. Yamamoto Y, Okamura Y, Uemura S, Sugiura T, Ito T, Ashida R, et al. : Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor. *Ann Surg Oncol* 2017; 24: 2363-2370
102. Kim C, Byun JH, Hong SM, An S, Kim JH, Lee

- SS, et al. : A comparison of enhancement patterns on dynamic enhanced CT and survival between patients with pancreatic neuroendocrine tumors with and without intratumoral fibrosis. *Abdom Radiol (NY)* 2017; 42: 2835-2842
103. Tomimaru Y, Eguchi H, Tatsumi M, Kim T, Hama N, Wada H, et al. : Clinical utility of 2- [(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors. *Surgery* 2015; 157: 269-276
104. Kawamoto S, Johnson PT, Shi C, Singhi AD, Hruban RH, Wolfgang CL, et al. : Pancreatic neuroendocrine tumor with cystlike changes: evaluation with MDCT. *AJR Am J Roentgenol* 2013; 200: W283-90
105. Cloyd JM, Kopecky KE, Norton JA, Kunz PL, Fisher GA, Visser BC, et al. : Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis. *Surgery* 2016; 160: 708-713
106. Falconi M, Plockinger U, Kwekkeboom DJ, Manfredi R, Korner M, Kvols L, et al. : Frascati Consensus Conference; European Neuroendocrine Tumor Society: Well-differentiated pancreatic nonfunctioning tumors/carcinoma. *Neuroendocrinology* 2006; 84: 196-211
107. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, et al. : North American Neuroendocrine Tumor Society (NANETS): NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. *Pancreas* 2010; 39: 735-752
108. Crippa S, Bassi C, Salvia R, Falconi M, Butturini G, Pederzoli P: Enucleation of pancreatic neoplasms. *Br J Surg* 2007; 94: 1254-1259
109. Crippa S, Bassi C, Warshaw AL, Falconi M, Partelli S, Thayer SP, et al. : Middle pancreatectomy: indications, short- and long-term operative outcomes. *Ann Surg* 2007; 246: 69-76
110. Falconi M, Zerbi A, Crippa S, Balzano G, Boninsegna L, Capitanio V, et al. : Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors. *Ann Surg Oncol* 2010; 17: 1621-1627
111. Pitt SC, Pitt HA, Baker MS, Christians K, Touzios JG, Kiely JM, et al. : Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate? *J Gastrointest Surg* 2009; 13: 1692-1698
112. Wermers RA, Fatourech V, Wynne AG, Kvols LK, Lloyd RV: The glucagonoma syndrome. Clinical and pathologic features in 21 patients. *Medicine (Baltimore)* 1996; 75: 53-63
113. Kindmark H, Sundin A, Granberg D, Dunder K, Skogseid B, Janson ET, et al. : Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years. *Med Oncol* 2007; 24: 330-337
114. Soga J, Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. *J Exp Clin Cancer Res* 1999; 18: 13-22
115. Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ: Pancreatic VIPomas: subject review and one institutional experience. *J Gastrointest Surg* 2008; 12: 382-393
116. Klöppel G, Perren A, Heitz PU: The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. *Ann N Y Acad Sci* 2004 ; 1014 : 13-27
117. Zhu L, Xue HD, Sun H, Wang X, He YL, Jin ZY, et al. : Isoattenuating insulinomas at biphasic contrast-enhanced CT: frequency, clinicopathologic features and perfusion characteristics. *Eur Radiol* 2016; 26: 3697-3705
118. Yoo YJ, Yang SJ, Hwang HK, Kang CM, Kim H, Lee WJ: Overestimated Oncologic Significance of Lymph Node Metastasis in G1 Nonfunctioning Neuroendocrine Tumor in the Left Side of the Pancreas. *Medicine (Baltimore)* 2015; 94: e1404
119. Faitot F, Gaujoux S, Barbier L, Novaes M, Dokmak S, Aussilhou B, et al. : Reappraisal of pancreatic enucleations: A single-center experience of 126 procedures. *Surgery* 2015; 158: 201-210.
120. Cherif R, Gaujoux S, Couvelard A, Dokmak S, Vuillerme MP, Ruszniewski P, et al. : Parenchyma-sparing resections for pancreatic neuroendocrine tumors. *J Gastrointest Surg* 2012; 16: 2045-2055
121. Bisharat N, Omari H, Lavi I, Raz R: Risk of infection and death among post-splenectomy patients. *J Infect* 2001; 43: 182-186
122. Robinette CD, Fraumeni JF Jr: Splenectomy and subsequent mortality in veterans of the 1939-45 war. *Lancet* 1977; 2: 127-129
123. Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O: Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. *Haematologica* 2014; 99: 392-398
124. Pimpl W, Dapunt O, Kaindl H, Thalhamer J: Incidence of septic and thromboembolic-related deaths after splenectomy in adults. *Br J Surg* 1989; 76: 517-521
125. Fernández-Cruz L, Blanco L, Cosa R, Rendón H:

- Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors?. *World J Surg* 2008 ; 32 : 904-917
126. Gumbs AA, Grès P, Madureira F, Gayet B: Laparoscopic vs open resection of pancreatic endocrine neoplasms: single institution's experience over 14 years. *Langenbecks Arch Surg* 2008; 393: 391-395
127. Zhao YP, Zhan HX, Zhang TP, Cong L, Dai MH, Liao Q, et al. : Surgical management of patients with insulinomas: Result of 292 cases in a single institution. *J Surg Oncol* 2011; 103: 169-174
128. Gao H, Liu L, Wang W, Xu H, Jin K, Wu C, et al. : Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor. *Cancer Lett* 2018; 412: 188-193
129. Sallinen VJ, Le Large TTY, Tieftrunk E, Galeev S, Kovalenko Z, Haugvik SP, et al. : Prognosis of sporadic resected small (≤ 2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study. *HPB (Oxford)* 2018; 20: 251-259
130. Liu TC, Hamilton N, Hawkins W, Gao F, Cao D: Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors. *Am J Surg Pathol* 2013; 37: 853-859
131. Lopez-Aguilar AG, Ethun CG, Postlewait LM, Zhelnin K, Krasinskas A, El-Rayes BF, et al. : Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease. *Ann Surg Oncol* 2018; 25: 290-298
132. Bonney GK, Gomez D, Rahman SH, Verbeke CS, Prasad KR, Toogood GJ, et al. : Results following surgical resection for malignant pancreatic neuroendocrine tumours. A single institutional experience. *JOP* 2008; 9: 19-25
133. Strosberg JR, Cheema A, Weber JM, Ghayouri M, Han G, Hodul PJ, et al. : Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. *Ann Surg* 2012; 256: 321-325
134. Crippa S, Zerbi A, Boninsegna L, Capitanio V, Partelli S, Balzano G, et al. : Surgical management of insulinomas: short- and long-term outcomes after enucleations and pancreatic resections. *Arch Surg* 2012; 147: 261-266
135. Nikfarjam M, Warshaw AL, Axelrod L, Deshpande V, Thayer SP, Ferrone CR, et al. : Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. *Ann Surg* 2008; 247: 165-172
136. Kimura W, Tezuka K, Hirai I: Surgical management of pancreatic neuroendocrine tumors. *Surg Today* 2011; 41: 1332-1343
137. Kimura W, Yano M, Sugawara S, Okazaki S, Sato T, Moriya T, et al. : Spleen-preserving distal pancreatectomy with conservation of the splenic artery and vein: techniques and its significance. *J Hepatobiliary Pancreat Sci* 2010; 17: 813-823
138. Kimura W, Inoue T, Futakawa N, Shinkai H, Han I, Muto T: Spleen-preserving distal pancreatectomy with conservation of the splenic artery and vein. *Surgery* 1996; 120: 885-890
139. Ardengh JC, Rosenbaum P, Ganc AJ, Goldenberg A, Lobo EJ, Malheiros CA, et al. : Role of EUS in the preoperative localization of insulinomas compared with spiral CT. *Gastrointest Endosc* 2000 ; 51 : 552-555
140. Gouya H, Vignaux O, Augui J, Dousset B, Palazzo L, Louvel A, et al. : CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. *AJR Am J Roentgenol* 2003; 181: 987-992
141. McLean AM, Fairclough PD: Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. *Best Pract Res Clin Endocrinol Metab* 2005; 19: 177-193
142. Nawata S, Sakurai F, Hirai I, Nawata S, Kimura W: Surgical management of insulinoma. Special reference to the enucleation procedure for insulinoma located in the head of the pancreas (in Japanese). *Suizo (Jpn J Panc Soc)* 2002; 17: 114-119
143. Kimura W: Surgical anatomy of the pancreas for limited resection. *J Hepato-Biliary-Pancreatic Surg* 2000; 7: 473-479
144. Tezuka K, Kimura W, Hirai I, Moriya T, Watanabe T, Yano M: Postoperative hematological changes after spleen-preserving distal pancreatectomy with preservation of the splenic artery and vein. *Dig Surg* 2012; 29: 157-164
145. Bonderman D, Jakowitsch J, Adlbrecht C, Schemper M, Kyrle PA, Schönauer V, et al. : Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. *Thromb Haemost* 2005; 93: 512-516
146. Holdsworth RJ, Irving AD, Cuschieri A: Postsplenectomy sepsis and its mortality rate: actual versus perceived risks. *Br J Surg* 1991; 78: 1031-1038

147. Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers GD, Jean ME, et al. : Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. *Surgery* 2001; 130: 1078-1085
148. Evans DB, Skibber JM, Lee JE, Cleary KR, Ajani JA, Gagel RF, et al. : Nonfunctioning islet cell carcinoma of the pancreas. *Surgery* 1993; 114: 1175-1182
149. Fraker DL, Norton JA, Alexander HR, Venzon DJ, Jensen RT: Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. *Ann Surg* 1994; 220: 320-330
150. Capurso G, Bettini R, Rinzivillo M, Boninsegna L, Delle Fave G, Falconi M: Role of Resection of the Primary Pancreatic Neuroendocrine Tumour Only in Patients with Unresectable Metastatic Liver Disease: A Systematic Review. *Neuroendocrinology* 2011; 93: 223-229
151. Bettini R, Mantovani W, Boninsegna L, Crippa S, Capelli P, Bassi C, et al. : Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. *Dig Liver Dis* 2009; 41: 49-55
152. Hung JS, Chang MC, Lee PH, Tien YW: Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases? *World J Surg* 2007; 31: 2392-2397
153. Bloomston M, Muscarella P, Shah MH, Frankel WL, Al-Saif O, Martin EW, et al. : Cytoreduction results in high perioperative mortality and decreased survival in patients undergoing pancreatectomy for neuroendocrine tumors of the pancreas. *J Gastrointest Surg* 2006; 10: 1361-1370
154. Bruzoni M, Parikh P, Celis R, Are C, Ly QP, Meza JL, et al. : Management of the primary tumor in patients with metastatic pancreatic neuroendocrine tumor: a contemporary single-institution review. *Am J Surg* 2009; 197:376-381
155. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, et al. : Neuroendocrine hepatic metastases: does aggressive management improve survival? *Ann Surg* 2005; 241: 776-785
156. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT: Aggressive surgery for metastatic liver neuroendocrine tumors. *Surgery* 2003; 134: 1057-1065
157. Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet JF, Dromain C, et al. : Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. *Surgery* 2003; 133: 375-382
158. Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plöckinger U: Multimodal management of neuroendocrine liver metastases. *HPB (Oxford)* 2010; 12: 361-379
159. Stoeltzing O, Loss M, Huber E, Gross V, Eilles C, Mueller-Brand J, et al. : Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. *Langenbecks Arch Surg* 2010; 395: 185-192
160. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, et al. : Hepatic neuroendocrine metastases: does intervention alter outcomes? *J Am Coll Surg* 2000; 190: 432-445
161. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG: Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. *J Am Coll Surg* 2003; 197: 29-37
162. Gomez D, Malik HZ, Al-Mukthar A, Menon KV, Toogood GJ, Lodge JP, et al. : Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. *HPB (Oxford)* 2007; 9: 345-351
163. Cho CS, Labow DM, Tang L, Klimstra DS, Loeffler AG, Levenson GE, et al. : Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. *Cancer* 2008; 113: 126-134
164. Scigliano S, Lebtahi R, Maire F, Stievenart JL, Kianmanesh R, Sauvanet A, et al. : Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. *Endocr Relat Cancer* 2009; 16: 977-990
165. Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC, et al. : Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. *Ann Surg Oncol* 2010; 17: 3129-3136
166. Glazer ES, Tseng JF, Al-Refaie W, Solorzano CC, Liu P, Willborn KA, et al. : Long-term survival after surgical management of neuroendocrine hepatic metastases. *HPB (Oxford)* 2010; 12: 427-433
167. Saxena A, Chua TC, Sarkar A, Chu F, Liauw W, Zhao J, et al. : Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. *Surgery* 2011; 149: 209-220
168. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti

- MA: Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? *J Am Coll Surg* 1998; 187: 88-93
169. Thompson GB, van Heerden JA, Grant CS, Carney JA, Ilstrup DM: Islet cell carcinomas of the pancreas: a twenty-year experience. *Surgery* 1988; 104: 1011-1017
170. Carty SE, Jensen RT, Norton JA: Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. *Surgery* 1992; 112: 1024-1032
171. Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, et al. : Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. *Cancer* 2009; 115: 741-751
172. Steinmüller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, et al. : Consensus guidelines for the management of patients with liver metastases from digestive (neuro) endocrine tumors: foregut, midgut, hindgut, and unknown primary. *Neuroendocrinology* 2008; 87: 47-62
173. Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE: Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. *Br J Surg* 2009; 96: 175-184
174. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapis Y: Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. *World J Surg* 1996; 20: 908-915
175. Elias D, Lefevre JH, Duvillard P, Goéré D, Dromain C, Dumont F, et al. : Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination: they are many more than you think.. *Ann Surg* 2010; 251: 307-310
176. Maire F, Hammel P, Kianmanesh R, Hentic O, Couvelard A, Rebours V, et al. : Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? *Surgery* 2009; 145: 69-75
177. Kianmanesh R, Sauvanet A, Hentic O, Couvelard A, Lévy P, Vilgrain V, et al. : Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. *Ann Surg* 2008; 247: 659-665
178. De Jong MC, Farnell MB, Scwabas G, Cunningham SC, Cameron JL, Geschwind JF, et al. : Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. *Ann Surg* 2010; 252: 142-148
179. Eriksson B, Arnberg H, Lindgren PG, Lörelus LE, Magnusson A, Lundqvist G, et al. : Neuroendocrine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients. *J Intern Med* 1990; 228: 103-113
180. Metz DC, Jensen RT: Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. *Gastroenterology* 2008; 135: 1469-1492
181. Mayo SC, de Jong MC, Bloomston M, Pulitano C, Clary BM, Reddy SK, et al. : Surgery Versus Intra-arterial Therapy for Neuroendocrine Liver Metastasis: A Multicenter International Analysis. *Ann Surg Oncol* 2011; 18: 3657-3665
182. Yalcin S: Advances in the systemic treatment of pancreatic neuroendocrine tumors. *Cancer Treat Rev* 2011; 37: 127-132
183. Shah T, Caplin M: Endocrine tumours of the gastrointestinal tract. *Biotherapy for metastatic endocrine tumours. Best Pract Res Clin Gastroenterol* 2005; 19: 617-636
184. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. : Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3] octreotate: toxicity, efficacy, and survival. *J Clin Oncol* 2008; 26: 2124-2130
185. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. : RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med* 2011; 364: 514-523
186. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. *N Engl J Med* 2011; 364: 501-513
187. Lehnert T: Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. *Transplantation* 1998; 66: 1307-1312
188. Ahlman H, Fridman S, Cahlin C, Nilsson O, Jansson S, Wängberg B, et al. : Liver transplantation for treatment of metastatic neuroendocrine tumors. *Ann N Y Acad Sci* 2004; 1014: 265-269
189. Rosenau J, Bahr MJ, von Wasielewski R, Mengel M, Schmidt HH, Nashan B, et al. : Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. *Transplantation* 2002; 73: 386-394
190. Lang H, Oldhafer KJ, Weimann A, Schlitt HJ, Scheumann GF, Flemming P, et al. : Liver transplantation for metastatic neuroendocrine tumors. *Ann Surg* 1997; 225: 347-354

191. Le Treut YP, Grégoire E, Belghiti J, Boillot O, Soubrane O, Mantion G, et al. : Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. *Am J Transplant* 2008; 8: 1205-1213
192. Máthé Z, Tagkalos E, Paul A, Molmenti EP, Kóbori L, Fouzas I, et al. : Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis. *Transplantation* 2011; 91: 575-582
193. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS: Cytoreductive hepatic surgery for neuroendocrine tumors. *Surgery* 1990; 108: 1091-1096
194. Modlin IM, Lewis JJ, Ahlman H, Bilchik AJ, Kumar RR: Management of unresectable malignant endocrine tumors of the pancreas. *Surg Gynecol Obstet* 1993; 176: 507-518
195. Wessels FJ, Schell SR: Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. *J Surg Res* 2001; 95: 8-12
196. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK: Hepatic resection for metastatic neuroendocrine carcinomas. *Am J Surg* 1995; 169: 36-43
197. Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, et al. : Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. *Ann Surg Oncol* 2006; 13: 572-581
198. Chung MH, Pisegna J, Spirt M, Giuliano AE, Ye W, Ramming KP, et al. : Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. *Surgery* 2001; 130: 954-962
199. Khan JH, McElhinney DB, Rahman SB, George TI, Clark OH, Merrick SH: Pulmonary metastases of endocrine origin: the role of surgery. *Chest* 1998; 114: 526-534
200. Elias D, Sideris L, Liberale G, Ducreux M, Malka D, Lasser P, et al. : Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. *Surgery* 2005; 137: 411-416
201. Vasseur B, Cadiot G, Zins M, Fléjou JF, Belghiti J, Marmuse JP, et al. : Peritoneal carcinomatosis in patients with digestive endocrine tumors. *Cancer* 1996; 78: 1686-1692
202. Schurr PG, Strate T, Rese K, Kaifi JT, Reichelt U, Petri S, et al. : Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. *Ann Surg* 2007; 245: 273-281
203. Sata N, Kimura W, Kanazawa T, Muto T: Malignant insulinoma causing liver metastasis 8 years after the initial surgery: report of a case. *Surg Today* 1995; 25: 640-642
204. Oberg K, Akerström G, Rindi G, Jelic S; ESMO Guidelines Working Group: Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2010; 21 (Suppl. 5): v223-227
205. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, et al. : Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. *J Nucl Med* 1997; 38: 853-858
206. Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, et al. : Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-enteropancreatic tumours. *Eur J Nucl Med* 1998; 25: 1396-1403
207. Arnold R, Chen YJ, Costa F, Falconi M, Gross D, Grossman AB, et al. : ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors : follow-up and documentation. *Neuroendocrinology* 2009; 90: 227-233
208. Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, et al. : Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. *Clin Gastroenterol Hepatol* 2008; 6: 820-827
209. Nikou GC, Marinou K, Thomakos P, Papageorgiou D, Sanzanidis V, Nikolaou P, et al. : Chromogranin A levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours. *Pancreatology* 2008; 8: 510-519
210. Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, et al. : Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. *Cancer* 1999; 86: 858-865
211. Schillaci O, Spanu A, Scopinaro F, Falchi A, Danieli R, Marongiu P, et al. : Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. *J Nucl Med* 2003; 44: 359-368